CN104888119A - Traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and preparation method thereof Download PDFInfo
- Publication number
- CN104888119A CN104888119A CN201510315446.8A CN201510315446A CN104888119A CN 104888119 A CN104888119 A CN 104888119A CN 201510315446 A CN201510315446 A CN 201510315446A CN 104888119 A CN104888119 A CN 104888119A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- atrophic gastritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia. The traditional Chinese medicine composition is prepared from the following crude drugs in parts by weight: 10-20 parts of Chinese yam, 10-20 parts of radix codonopsis, 10-20 parts of parched white peony root, 8-12 parts of stir-baked fructus crataegi, 8-12 parts of radix asparagi, 8-12 parts of radix ophiopogonis, 8-12 parts of radix curcumae, 8-12 parts of angelica sinensis, 8-12 parts of fructus toosendan, 8-12 parts of colla corii asini, 8-12 parts of fructus citri sarcodactylis, 15-30 parts of hedyotis diffusa, 8-12 parts of radix paeoniae rubra, 1-5 parts of pseudo-ginseng, 8-15 parts of radix bupleuri and 4-8 parts of liquorice. According to the traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia, the crude drugs are firstly subjected to conventional treatment, crushed into fine powder, sieved with a 100-mesh sieve, and then mixed uniformly, and finally the powdered traditional Chinese medicine composition is obtained and then encapsulated according to a conventional technological method to be prepared into hard capsules with the specification of 0.4 g/grain. The traditional Chinese medicine composition has the effects of benefiting qi and nourishing yin, promoting blood circulation to remove meridian obstruction, clearing liver to relieve heat and promoting digestion, is used for treating chronic atrophic gastritis with intestinal metaplasia, can effectively improve symptoms and physical signs and promote repair of injured gastric mucosa.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, be specifically related to a kind of Chinese medicine composition and preparation method for the treatment of chronic atrophic gastritis companion intestinal.
Background technology
Chronic gastritis refers to chronic inflammatory disease or the atrophic lesion of the gastric mucosa that different pathogeny causes, very common clinically.In conjunction with clinical, scope and histopathology result, chronic gastritis is divided into shallow, atrophic and specific type gastritis three class.
Chronic atrophic gastritis (Chronic Atrophic Gastritis, CAG) is agnogenic chronic gastritis, belongs to common clinical, frequently-occurring disease, in chronic gastritis, accounts for 10% ~ 30%.This sick clinical manifestation lacks specific symptom, most patient is early early stage often asymptomatic or have the indigestion symptom of varying degree as upper abdomen dull pain, loss of appetite, post-prandial fullness, acid regurgitation, feel sick, and severe atrophy gastritis sufferer can have anemia, becomes thin, glossitis, diarrhoea etc.Primary disease is that, muscularis mucosae thinning with gastric epithelial and body of gland atrophy, mucosa thickens and the chronic disease that is feature with intestinal gland metaplasia, atypical hyperplasia.Most scholars approves of chronic gastritis → Mucosal atrophy → intestinal epithelial metaplasia → dysplasia → stomach cancer development pattern both at home and abroad at present.
Chronic atrophic gastritis (CAG) is the disease that a kind of canceration rate is very high, is especially often called precancerous lesion with pathological change persons such as atypical hyperplasia and intestinalization lifes.How to find a kind of effectively can block CAG development method and medicine become a focus of at present research gastric cancer primary prevention, active treatment CAG is its canceration of prevention, reduces the effective means of incidence gastric cancer rate.
Summary of the invention
Technical problem to be solved by this invention is for the deficiencies in the prior art, and provides a kind of Chinese medicine composition for the treatment of chronic atrophic gastritis companion intestinal, and this Chinese medicine composition name of product called after GUISHAO disappears the intestinal capsule that withers; Chinese medicine composition enriching yin boost qi of the present invention, heat clearing away resolving depression, dehumidifies soothing the liver, effectively can improve symptom and sign, and promotes the reparation of damage gastric mucosa.
Another object of the present invention is to provide a kind of preparation method of above-mentioned Chinese medicine composition.
To achieve these goals, the present invention adopts following technical scheme:
Treat a Chinese medicine composition for atrophic gastritis accompanied intestinal, the crude drug comprising following weight portion is made: Rhizoma Dioscoreae 10-20 part, Radix Codonopsis 10-20 part, Radix Paeoniae Alba (parched) 10-20 part, Fructus Crataegi (parched) 8-12 part, Radix Asparagi 8-12 part, Radix Ophiopogonis 8-12 part, Radix Curcumae 8-12 part, Radix Angelicae Sinensis 8-12 part, Fructus Toosendan 8-12 part, Colla Corii Asini 8-12 part, Fructus Citri Sarcodactylis 8-12 part, Herba Hedyotidis Diffusae 15-30 part, Radix Paeoniae Rubra 8-12 part, Radix Notoginseng 1-5 part, Radix Bupleuri 8-15 part, Radix Glycyrrhizae 4-8 part.
In the preferred technical scheme of the present invention, comprise crude drug: Rhizoma Dioscoreae 15 parts, Radix Codonopsis 15 parts, Radix Paeoniae Alba (parched) 15 parts, Fructus Crataegi (parched) 10 parts, Radix Asparagi 10 parts, Radix Ophiopogonis 10 parts, Radix Curcumae 10 parts, Radix Angelicae Sinensis 10 parts, Fructus Toosendan 10 parts, 10 parts, Colla Corii Asini, Fructus Citri Sarcodactylis 10 parts, Herba Hedyotidis Diffusae 20 parts, Radix Paeoniae Rubra 10 parts, Radix Notoginseng 3 parts, Radix Bupleuri 12 parts, 6 parts, Radix Glycyrrhizae.
The present invention also provides a kind of preparation method of above-mentioned Chinese medicine composition, and above-mentioned each crude drug is directly ground into fine powder after conventional treatment, crosses 100 mesh sieves, Powdered Chinese medicine composition is obtained after mixing, this Chinese medicine composition is celandine green powder, and gas is fragrant, acrid in the mouth, hardship.
Described crude drug is through conventional treatment, and that refer to necessity that crude drug is recorded according to " Chinese Pharmacopoeia " (2010) reference book, conventional processing procedure processes.
In preferred version of the present invention, further described Chinese medicine composition is loaded hard capsule according to a conventional method, make capsule.
Described capsule, specification is 0.4g/ every.
The instructions of taking of Chinese medicine composition of the present invention is:
One people 3 times on the one, each 3-5 grain; A maximum consumption per day of being grown up is 4g/d.
In formula of the present invention, using Radix Codonopsis and Rhizoma Dioscoreae as monarch drug: Radix Codonopsis sweet in the mouth is gentle, there is QI invigorating invigorating middle warmer, the effect of nourishing blood of promoting the production of body fluid, it is the qi-invigorating herb often used, quench one's thirst for deficiency of the spleen and lung, cardiopalmus of breathing hard, anorexia and loose stool, dyspnea due to deficiency cough, interior-heat, we get its QI invigorating invigorating middle warmer, the effect of invigorating the spleen and regulating the stomach; Rhizoma Dioscoreae sweet in the mouth, property are flat, enter lung, spleen, kidney channel, not dry oiliness, there is spleen reinforcing nourishing the stomach, effect of the lung benefiting that promotes the production of body fluid, the kidney invigorating arresting seminal emission, breath with cough for insufficiency of the spleen lack of appetite, incessant chronic diarrhea, the deficiency of the lung, emission due to deficiency of the kidney, leukorrhagia, frequent micturition, deficiency-heat quench one's thirst, we get the effect of its spleen reinforcing nourishing the stomach and Radix Codonopsis is monarch drug invigorating the spleen and benefiting QI stomach function regulating altogether.With Radix Asparagi, Radix Ophiopogonis (another name: Radix Ophiopogonis) yin nourishing reinforcing stomach reg fluid: Radix Asparagi is the tuber of liliaceous plant Radix Asparagi, YIN nourishing, moisturize, lung heat clearing, pathogenic fire reducing; Radix Ophiopogonis nourishing YIN and moistening the lung, the relieving restlessness that clears away heart-fire, reinforcing stomach reg fluid, control dryness of the lung dry cough, haematemesis, spitting of blood, consumptive lung disease, lung abscess, asthenia dysphoria with smothery sensation, quench one's thirst, calentura Tianjin wound, dry mouth and throat, constipation, we get its reinforcing stomach reg fluid and Radix Asparagi shares yin nourishing reinforcing stomach reg fluid, join monarch drug invigorating the spleen and benefiting QI, the stomach function regulating that promotes the production of body fluid is ministerial drug.Assistant is with Radix Curcumae, Fructus Toosendan, Radix Paeoniae Alba (parched), Radix Bupleuri, Fructus Citri Sarcodactylis depressed liver-energy dispersing and QI regulating and stomach and alleviating pain; Colla Corii Asini, the Radix Paeoniae Alba are enriched blood YIN nourishing; Radix Angelicae Sinensis, Radix Paeoniae Rubra, pseudo-ginseng blood-circulation-invigovating removing obstruction in the collateral to relieve pain tissue regeneration promoting; Herba Hedyotidis Diffusae, Fructus Crataegi (parched) clearing away heat and promoting digestion regulating the stomach and easing middleJIAO; Radix Glycyrrhizae replenishing QI to invigorate the spleen coordinating the actions of various ingredients in a prescription.Full side reaches benefiting qi and nourishing yin, promoting blood circulation to remove obstruction in the collateral, and Shugan Qingre helps digestion and can the real good recipe raw for treatment atrophic gastritis accompanied intestinalization of pain relieving tissue regeneration promoting.
Chinese medicine composition of the present invention, benefiting qi and nourishing yin, promoting blood circulation to remove obstruction in the collateral, Shugan Qingre help digestion, and are used for the treatment of atrophic gastritis accompanied intestinalization raw, effectively can improve symptom and sign, and promote the reparation of damage gastric mucosa.
The effect of the treatment chronic atrophic gastritis companion intestinal of Chinese medicine composition of the present invention can with reference to following zoopery:
One, Chinese medicine composition of the present invention is to the protective effect of chronic atrophic gastritis rat model:
1, material
1.1, animal, environment and feedstuff:
Animal: Wistar male rat 70, body weight 180 ~ 200g, pleases laboratory animal by Jinan friend and breeds company limited and provide, quality certification SCXK (Shandong) 20140007; Environment: Shandong Province's Experimental Animal Center, credit number: SYXK (Shandong) 20140010; Rat maintains feedstuff: Beijing HFK Bio-Technology Co., Ltd. provides, production licence number: SCXK (capital) 20090008.
1.2, medicine:
By reagent: pharmaceutical composition prepared by the embodiment of the present invention 1, a consumption per day of being grown up is 176g crude drug, according to people and rat body surface area scaling method, calculating rat dosage on the one is 176 × 0.018 × 5g/kg=15.84g/kg ≈ 16g/kg, dosage three dosage component are not according to 4 of clinical equivalent amount, 2, 1 times, namely 64g/kg (experiment high dose group) is respectively, 32g/kg (in experiment dosage group), 16g/kg (experiment low dose group), administration volume is 10ml/kg, being mixed with containing crude drug amount concentration before use is respectively 6.4g/ml, 3.2g/ml, the decocting liquid of 1.6g/ml is for subsequent use.
Contrast medicine: Vitamycin coated tablet (Hubei green gold Pharmaceutical Co., Ltd product, lot number: 130903), Vitamycin matched group administration 0.3g/kg (being equivalent to clinical equimultiple dosage of being grown up), pulverize and make suspension with distilled water, the concentration of suspension is 0.03g/ml.
1.3, reagent:
Sodium salicylate: Chemical Reagent Co., Ltd., Sinopharm Group produces (lot number T20140125).Serum gastrin (GAS), Plasma Motilin Levels and Colonic Motility (MTL) detection kit: Beijing.
1.4, instrument:
DDL-5 type low speed refrigerated centrifuge: Anting Scientific Instrument Factory, Shanghai's product; ELX808 type microplate reader: Bio Rad Laboratories.
2, method:
2.1, animal grouping and model are set up:
Raised by 70 Wistar rat adaptabilities after 7d and randomly draw 12 as blank group, all the other are modeling group; Normal group routine is raised, modeling group rat with reference to the report such as Huang Yahui chronic atrophic gastritis modeling method (Huang Yahui, Wang Qinghui, Chen Xiaoyan, etc.; Flat relaxing of withering treats chronic atrophic gastritis experimentation [J]. Chinese combination of Chinese and Western medicine digestion magazine, 2002,10 (1): 18-20) carry out modeling:
I.e. 2% sodium salicylate solution 2mL/ gavage, continuous 6 weeks; 1h fasting before and after gavage, taboo water; First 3 weeks ad lib standard mouse food; Odd-numbered day fasting in latter 3 week, freely drinks water, and even-numbered days, enough feedings, freely drank water; Swim in the warm water of 25 DEG C after feed, each 10min; Modeling terminates rear blank group and randomly draws 2, and modeling group randomly draws 4 execution, confirms modelling success through pathologic finding; From modeling group rat, choose 50, be divided into dosage group and experiment low dose group in model control group, Vitamycin matched group, experiment high dose group, experiment at random, often organize 10.
2.2 administration
The normal saline of the rat difference gavage 10ml/kg of blank group and model control group; The rat tested liquid medicine decocting liquid of gavage or the suspension 10ml/kg respectively of dosage group and experiment low dose group in Vitamycin matched group, experiment high dose group, experiment, every day is administered once, continuous 30d, takes weekly body weight 1 time, according to body weight adjustment dosage.
2.3, collection of specimens and detection:
Last administration, after water 12h is can't help in each treated animal fasting, 5% pentobarbital sodium presses 50mg/kg, intraperitoneal anesthesia, ventral aorta blood sampling 5ml, average mark is placed in common test tube and EDTA anticoagulant test tube, 3000r/min, centrifugal 15min, centrifugal serum and plasma-20 DEG C saves backup.Take full stomach specimen fast, cut off body of stomach along greater gastric curvature, after washing away gastric content with normal saline, get lesser gastric curvature side gastric antrum portion 0.5cm × 2cm size gastric tissue be placed in 10% formaldehyde fix, paraffin embedding, be HE dyeing, observe Histopathologic changes.
Serum gastrin (GAS), Plasma Motilin Levels and Colonic Motility (MTL) detect and all adopt enzyme linked immunosorbent assay (ELISA) to detect, and are undertaken by the operating instruction provided in test kit.
2.4, statistical method:
Application SPSS 17.00 software carries out statistical analysis, and all data mean ± standard deviation represents, carries out one factor analysis of variance between measurement data group.
3, result:
3.1, general status:
The general status of blank group rat is good, and food of receiving is normal; There is lethargy in model control group rat, food-intake declines, and body weight comparatively blank group alleviates, and hair matter is withered, hair color tarnishes, the performances such as loose stool.Each treatment group rat is in experimentation, and all occur that spirit in various degree takes a turn for the better, appetite amelioration, symptom all comparatively model is light, and body weight increases, wherein obvious with the improvement of testing high dose group.
3.2 are subject to reagent on the impact of rat model serum GAS, motilin in plasma:
Rat blood serum gastrin and plasma motilin is measured according to test kit description, result is as shown in table 1, in model control group rat blood, gastrin obviously reduces, and motilin obviously raises, and more all has significant difference (P<0.01) with blank group; With the more each administration group of model control group raising rat model GAS serum levels all in various degree, reduce rat plasma MTL level, result is as shown in table 1, proves that Chinese medicine composition of the present invention has the pharmacodynamic action improving rat stomach secretin and motilin.
Table 1 is subject to reagent on the impact of rat model serum GAS, motilin in plasma
Note: compare with model control group, " * " P<0.05, " * * " P<0.01.
3.3, gastric mucosa pathological change:
3.2.1 perusal:
Blank group gastric mucosa is powder/pale red, and surperficial ditch returns obviously, level and smooth gloss, and tunica muscularis gastris is abundant; Model control group gastric mucosa is dark red or canescence, the blood vessel that tunica muscularis gastris appears as seen, and surperficial ditch returns and shoals, tarnishes, accidental gastric mucosa ulcer focus; Each treatment group gastric mucosa surface all comparatively model group takes a turn for the better.
3.2.2 om observation:
Blank group gastric mucosa body of gland marshalling is tight, has no the pathological changes (as shown in Figure 1) such as gastric mucosa necrosis, body of gland atrophy, intestinalization life and exception.Model control group gastric mucosa body of gland is not of uniform size, structure disturbance, body of gland atrophy (as shown in Figure 2).The arrangement of Vitamycin control rats gastric mucosa body of gland owes rule, cystic dilatation that gastric gland body is slight (as shown in Figure 3).Experiment high dose group gastric mucosa body of gland queueing discipline, has no obvious gastric mucosa downright bad, visible indivedual slight atrophy of body of gland (as shown in Figure 4).In experiment, rule is owed in the arrangement of dosage group gastric mucosa body of gland, occurs that a small amount of gastric gland body wall is thinning, atrophy, the cystic dilatation of gastric gland body, accidental gastric mucosa necrosis (as shown in Figure 5).Experiment low dose group gastric mucosa body of gland irregular arrangement, has that more gastric gland body wall is thinning, atrophy, gastric gland body cavity cystic dilatation (as shown in Figure 6); Prove that Chinese medicine composition of the present invention has the pharmacodynamic action improving gastric mucosa of rat.
Conclusion: give rat 2% sodium salicylate aqueous solution 6 weeks continuously, there is gastritis performance significantly in rat model; Give test medicine one month, each group of rat general status comparatively model group obviously improves, food-intake increases, level of serum gastrin compares with model group and has significant difference (P<0.01), wherein the high dose group rat of Chinese medicine composition of the present invention changes the most obvious, and the plasma motilin of high dose group rat compares with model control group and has significant significant difference (P<0.01).Histopathologic examination is visible, and model group rats gastric mucosa body of gland is not of uniform size, structure disturbance, body of gland atrophy; The high dose group gastric mucosa body of gland queueing discipline of Chinese medicine composition of the present invention, has no obvious gastric mucosa downright bad, visible indivedual slight atrophy of body of gland; Other each group is improved the pathological change of rat model mucosa tissue in various degree.In sum, Chinese medicine composition of the present invention has the pharmacodynamic action of clear and definite treatment chronic atrophic gastritis.
In addition, Chinese medicine composition of the present invention proves safe without toxic side effect through animal model acute toxicity test and long term toxicity test.
Accompanying drawing explanation
In Fig. 1, chronic atrophic gastritis model, the gastric mucosa tissue pathological picture of the rat of blank group;
In Fig. 2, chronic atrophic gastritis model, the gastric mucosa tissue pathological picture of the rat of model control group;
In Fig. 3, chronic atrophic gastritis model, the gastric mucosa tissue pathological picture of the rat of Vitamycin matched group;
In Fig. 4, chronic atrophic gastritis model, the gastric mucosa tissue pathological picture of the rat of experiment high dose group;
In Fig. 5, chronic atrophic gastritis model, the gastric mucosa tissue pathological picture of the rat of dosage group in experiment;
In Fig. 6, chronic atrophic gastritis model, the gastric mucosa tissue pathological picture of the rat of experiment low dose group.
Detailed description of the invention
Below the detailed description of the invention of technical solution of the present invention is described in detail, but the present invention is not limited to following description content:
Embodiment 1:
Treat a Chinese medicine composition for atrophic gastritis accompanied intestinal, comprise crude drug: Rhizoma Dioscoreae 15g, Radix Codonopsis 15g, Radix Paeoniae Alba (parched) 15g, Fructus Crataegi (parched) 10g, Radix Asparagi 10g, Radix Ophiopogonis 10g, Radix Curcumae 10g, Radix Angelicae Sinensis 10g, Fructus Toosendan 10g, Colla Corii Asini 10g, Fructus Citri Sarcodactylis 10g, Herba Hedyotidis Diffusae 20g, Radix Paeoniae Rubra 10g, Radix Notoginseng 3g, Radix Bupleuri 12g, Radix Glycyrrhizae 6g;
Above-mentioned each crude drug is directly ground into fine powder after the process of necessity, crosses 100 mesh sieves, after mixing, load hard capsule according to a conventional method, make capsule, capsule called after GUISHAO disappears the intestinal capsule that withers, and every containing Chinese medicine composition 0.4g.
Embodiment 2:
Treat a Chinese medicine composition for atrophic gastritis accompanied intestinal, comprise crude drug: Rhizoma Dioscoreae 10g, Radix Codonopsis 20g, Radix Paeoniae Alba (parched) 10g, Fructus Crataegi (parched) 12g, Radix Asparagi 8g, Radix Ophiopogonis 12g, Radix Curcumae 8g, Radix Angelicae Sinensis 12g, Fructus Toosendan 8g, Colla Corii Asini 12g, Fructus Citri Sarcodactylis 8g, Herba Hedyotidis Diffusae 30g, Radix Paeoniae Rubra 8g, Radix Notoginseng 5g, Radix Bupleuri 8g, Radix Glycyrrhizae 8g;
Above-mentioned each crude drug is directly ground into fine powder after the process of necessity, crosses 100 mesh sieves, after mixing, load hard capsule according to a conventional method, make capsule, capsule called after GUISHAO disappears the intestinal capsule that withers, and every containing Chinese medicine composition 0.4g.
Embodiment 3:
Treat a Chinese medicine composition for atrophic gastritis accompanied intestinal, comprise crude drug: Rhizoma Dioscoreae 20g, Radix Codonopsis 10g, Radix Paeoniae Alba (parched) 20g, Fructus Crataegi (parched) 8g, Radix Asparagi 12g, Radix Ophiopogonis 8g, Radix Curcumae 12g, Radix Angelicae Sinensis 8g, Fructus Toosendan 12g, Colla Corii Asini 8g, Fructus Citri Sarcodactylis 12g, Herba Hedyotidis Diffusae 15g, Radix Paeoniae Rubra 12g, Radix Notoginseng 1g, Radix Bupleuri 15g, Radix Glycyrrhizae 4g;
Above-mentioned each crude drug is directly ground into fine powder after the process of necessity, crosses 100 mesh sieves, after mixing, load hard capsule according to a conventional method, make capsule, capsule called after GUISHAO disappears the intestinal capsule that withers, and every containing Chinese medicine composition 0.4g.
Embodiment 4:
GUISHAO prepared by embodiment 1 disappears the clinical observation of intestinal capsule for treating atrophic gastritis accompanied intestinal of withering:
1, Therapeutic Method:
1.1, patient's grouping:
Select 2011-2013 years this Out-patient Department chronic atrophic gastritis companion intestinal epithelial metaplasia patient 68 examples, wherein male 33 example, women 35 example; At 43 ~ 70 years old age, all make a definite diagnosis through gastroscope and pathology of gastric mucosa biopsy, if gastroscope and the biopsy person of not being inconsistent, be as the criterion with biopsy results; Patient is without obvious specific symptom or with symptoms such as epigastrium dull pain, post-prandial fullness, acid regurgitation, loss of appetite for major part, gets rid of peptic ulcer, digestive tract tumor and other important organs functional defect person.
Selected patient is divided into matched group (34 example) and GUISHAO to disappear intestinal capsule for treating group (34 is routine) of withering with random digits table; In matched group patient man 18 example, female 16 example, 46 ~ 68 years old age, the mean age (44.18 ± 5.26) year; GUISHAO disappear wither intestinal capsule for treating group patient in man 19 example, female 15 example, 43 ~ 70 years old age, the mean age (43.95 ± 5.78) year; Two groups of patient's physical data comparing differences not statistically significant (P>0.05), have comparability.
1.2, Therapeutic Method:
Matched group patient gives doctor trained in Western medicine routine medication, comprises domperidone (10mg/ time, oral before the meal), bismuth potassium citrate (0.3g/ time, oral before the meal) and amoxicillin (0.5g/ time, 3 times/d); Disappear the wither patient of intestinal capsule for treating group of GUISHAO gives capsule for treating prepared by embodiment 1, and 2 times on the one, each 3-5 grain, maximum adult one consumption per day closes 4g/d.Two groups of patients are all 1 course for the treatment of with 14d, serve on 8 courses for the treatment of; Period avoids eating anything raw or cold, cure foods and excitant food, ban on opium-smoking and the opium trade alcohol prohibition.
1.3, detect:
Re-start gastroscopy after treatment terminates, and check result be analyzed, compare two groups of patient clinical treatment total effective rates,
Total effective rate: (curing number of cases+effectively number of cases)/total number of cases × 100%.
Curative effect determinate standard:
Cure: under clinical symptom disappearance and gastroscope, non-cancer lesion disappears completely; Gastroscope and pathology of gastric mucosa biopsy results more than 2 times and 2 times are all without intestinal epithelial metaplasia.Effective: symptom and sign is obviously alleviated, under gastroscope, non-cancer lesion area reduces >2/3, and gastroscope and the intestinal epithelial metaplasia of pathology of gastric mucosa biopsy results transfer moderate or slight to by severe, or moderate transfers to slightly.Effective: symptom and sign is alleviated to some extent, under gastroscope, non-cancer lesion area reduces 1/3 ~ 2/3, and intestinal epithelial metaplasia transfers moderate or slight to by severe, or moderate transfers to slightly.Invalid: clinical symptoms, gastroscope and pathology of gastric mucosa biopsy are all not improved.
1.4, statistical analysis:
Data inputting analysis software adopts Epidata3.04 and SPSS 18.0 respectively.Measurement data represents with mean ± standard deviation (x ± s), adopts t inspection; Enumeration data adopts χ
2inspection.P<0.05 is that difference has statistical significance.
2, result:
2.1 liang of group patient short term effects compare:
Two groups of patient's short term effect comparative results are in table 2, and as shown in Table 2, disappear wither patient's short term effect of intestinal capsule for treating group of GUISHAO is significantly better than matched group (P<0.05):
A table 2 liang group patient short term effect compares (n, %)
Note: two groups of total effective rates compare, " * " P<0.05.
Symptom and sign anomalous integral gastroscope integral contrast before and after 2.2 liang of group patient treatments:
After two groups of patient treatments symptom and sign anomalous integral gastroscope integration comparatively therapeutic outcome in table 3, as shown in Table 3, after two groups of patient treatments, symptom and sign anomalous integral gastroscope integration is significantly increased before comparatively treating, and GUISHAO disappear wither intestinal capsule for treating group patient treatment after two score level higher than matched group (P<0.05)
Symptom and sign anomalous integral gastroscope integral contrast before and after table 3 liang group patient treatment
Note: two groups of total effective rates compare, " * " P<0.05.
The above results shows that traditional Chinese medicine composition for treating chronic atrophic gastritis of the present invention effectively can improve symptom and sign, and promotes the reparation of damage gastric mucosa.
Above-mentioned example just for technical conceive of the present invention and technical characterstic are described, can not limit the scope of the invention with this.The equivalent transformation that all essence according to the present invention is done or modification, all should be encompassed within protection scope of the present invention.
Claims (4)
1. treat the Chinese medicine composition of chronic atrophic gastritis companion intestinal for one kind, it is characterized in that, the crude drug comprising following weight portion is made: Rhizoma Dioscoreae 10-20 part, Radix Codonopsis 10-20 part, Radix Paeoniae Alba (parched) 10-20 part, Fructus Crataegi (parched) 8-12 part, Radix Asparagi 8-12 part, Radix Ophiopogonis 8-12 part, Radix Curcumae 8-12 part, Radix Angelicae Sinensis 8-12 part, Fructus Toosendan 8-12 part, Colla Corii Asini 8-12 part, Fructus Citri Sarcodactylis 8-12 part, Herba Hedyotidis Diffusae 15-30 part, Radix Paeoniae Rubra 8-12 part, Radix Notoginseng 1-5 part, Radix Bupleuri 8-15 part, Radix Glycyrrhizae 4-8 part.
2. Chinese medicine composition according to claim 1, it is characterized in that, comprise Rhizoma Dioscoreae 15 parts, Radix Codonopsis 15 parts, Radix Paeoniae Alba (parched) 15 parts, Fructus Crataegi (parched) 10 parts, Radix Asparagi 10 parts, Radix Ophiopogonis 10 parts, Radix Curcumae 10 parts, Radix Angelicae Sinensis 10 parts, Fructus Toosendan 10 parts, 10 parts, Colla Corii Asini, Fructus Citri Sarcodactylis 10 parts, Herba Hedyotidis Diffusae 20 parts, Radix Paeoniae Rubra 10 parts, Radix Notoginseng 3 parts, Radix Bupleuri 12 parts, 6 parts, Radix Glycyrrhizae.
3. a preparation method for the Chinese medicine composition described in any one of claim 1 ~ 2, is directly ground into fine powder by above-mentioned each crude drug after conventional treatment, crosses 100 mesh sieves, obtains pulverous Chinese medicine composition after mixing.
4. preparation method according to claim 3, is characterized in that, further by described Chinese medicine composition process loading hard capsule routinely, makes capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510315446.8A CN104888119A (en) | 2015-06-10 | 2015-06-10 | Traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510315446.8A CN104888119A (en) | 2015-06-10 | 2015-06-10 | Traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104888119A true CN104888119A (en) | 2015-09-09 |
Family
ID=54021360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510315446.8A Pending CN104888119A (en) | 2015-06-10 | 2015-06-10 | Traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104888119A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107737296A (en) * | 2017-11-24 | 2018-02-27 | 刘萍 | A kind of medicine for treating atrophic gastritis and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110114346A (en) * | 2010-04-13 | 2011-10-19 | 목포대학교산학협력단 | Anti-cancer composition containing eriobotrya japonica extract |
| CN103566302A (en) * | 2013-10-23 | 2014-02-12 | 孙斌 | Traditional Chinese medicine for treating atrophic gastritis |
-
2015
- 2015-06-10 CN CN201510315446.8A patent/CN104888119A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110114346A (en) * | 2010-04-13 | 2011-10-19 | 목포대학교산학협력단 | Anti-cancer composition containing eriobotrya japonica extract |
| CN103566302A (en) * | 2013-10-23 | 2014-02-12 | 孙斌 | Traditional Chinese medicine for treating atrophic gastritis |
Non-Patent Citations (3)
| Title |
|---|
| 牛豫洁: "养胃法治疗慢性萎缩性胃炎近况", 《广西医学》 * |
| 范建场等: "《内科疾病诊疗基础》", 30 June 2007, 第四军医大学出版社 * |
| 陈政斌等: "疏肝养胃汤治疗慢性萎缩性胃炎31例", 《湖南中医学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107737296A (en) * | 2017-11-24 | 2018-02-27 | 刘萍 | A kind of medicine for treating atrophic gastritis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940832A (en) | Medicament for treating chronic bronchitis and preparation method thereof | |
| WO2022036779A1 (en) | Huashibaidu granule, preparation method therefor and anti-viral drug | |
| CN113827687B (en) | Traditional Chinese medicine formula preparation for treating thyroid nodule and preparation method thereof | |
| CN108653434A (en) | A kind of pharmaceutical composition for treating spleen emptiness and wet sputum type Stein-Leventhal syndrome | |
| CN105056128B (en) | A kind of Chinese medicine composition and preparation method and application for treating atrophic gastritis and intestines | |
| CN110339276A (en) | Traditional Chinese medicine for treating digestive tract tumor and preparation method thereof | |
| CN104888119A (en) | Traditional Chinese medicine composition for treating chronic atrophic gastritis with intestinal metaplasia and preparation method thereof | |
| CN114712478B (en) | Traditional Chinese medicine composition for treating intestinal diseases, preparation and preparation method thereof | |
| CN104771578A (en) | Traditional Chinese medicine for treating allergic rhinitis | |
| CN102614466B (en) | Traditional Chinese medical preparation for treatment of lung adenocarcinoma | |
| CN105521246A (en) | Medicinal preparation for treating lung cancer and applications of medicinal preparation | |
| CN101569717A (en) | Pharmaceutical composition for treating gastrointestinal diseases and cancer and preparation method thereof | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN104906472A (en) | Traditional Chinese medicine composition for preventing and treating cough-variant asthma | |
| CN109602790A (en) | A kind of Chinese medicine composition that treating malignant pleural effusion with lung cancer and its preparation and application | |
| CN104758442B (en) | It is a kind of to prevent and treat compound Chinese medicinal preparation of bronchial astehma and preparation method thereof | |
| CN102688469B (en) | Traditional Chinese medicine extract and preparation method and application thereof | |
| CN104491637B (en) | It is a kind of to treat compound composite medicament of cough after common cold and preparation method and application | |
| CN108066672A (en) | Emulsion for gynaecological imflammation and preparation method thereof | |
| CN105663551A (en) | Traditional Chinese medicine preparation for patient suffering from pancreatic cancer to take after operation as well as preparation method | |
| CN103751527A (en) | Traditional Chinese medicine composition for treating pulmonary fibrosis | |
| CN105232962A (en) | Traditional Chinese medicine composition for preparing medicines for treating skin diseases. | |
| CN105535429A (en) | Traditional Chinese medicine for treating Parkinson's disease and preparation method thereof | |
| WO2015149392A1 (en) | Preparation of traditional chinese medicine for treating chronic colitis and preparation method therefor | |
| CN106138670B (en) | A kind of cholagogue stomach function regulating, compound Chinese medicinal preparation of promoting blood circulation dehumidifying and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150909 |
|
| RJ01 | Rejection of invention patent application after publication |